Cytotoxic profile and peculiar reactivity with biomolecules of a novel "rule-breaker" iodidoplatinum(II) complex

ACS Medicinal Chemistry Letters

Volumn 1, Issue 8, 2010, Pages 381-385

  Messori, Luigi ^a   Casini, Angela ^b   Gabbiani, Chiara ^a   Michelucci, Elena ^a   Cubo, Leticia ^c   Ríos Luci, Carla ^d   Padrón, José M ^d   Navarro Ranninger, Carmen ^c   Quiroga, Adoracion G ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b EPFL   (Switzerland)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

cytotoxicity; DNA and protein interaction; Iodidoplatinum complex

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOCHROME C; DIIODIDODIISOPROPYLAMINE PLATINUM; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETER; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY;

EID: 78649234226     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100081e     Document Type: Article

References (31)

1. Todd, R. C.; Lippard, S. J. Inhibition of transcription by platinum antitumor compounds Metallomics 2009, 1, 280-291
2. Reedijk, J. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3611-3616
3. 4+ (BBR3464) Inorg. Chem. 2002, 41, 1101-1109
4. Hall, M. D.; Mellor, H. R.; Callaghan, R.; Hambley, T. W. Basis for design and development of platinum(IV) anticancer complexes J. Med. Chem. 2007, 50, 3403-11
5. Kelland, L. R.; Abel, G.; Mckeage, M. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Murrer, B. A.; Harrap, K. R. Preclinical Antitumor Evaluation of Bis-Acetato-Ammine-Dichloro-Cyclohexylamine Platinum(Iv)-an Orally Active Platinum Drug Cancer Res. 1993, 53, 2581-2586
6. Ma, Z. D.; Rao, L.; Bierbach, U. Replacement of a Thiourea-S with an Amidine-NH Donor Group in a Platinum-Acridine Antitumor Compound Reduces the Metal's Reactivity with Cysteine Sulfur J. Med. Chem. 2009, 52, 3424-3427
7. + J. Med. Chem. 1989, 32, 128-136
8. Perez, J. M.; Fuertes, M. A.; Alonso, C.; Navarro-Ranninger, C. Current status of the development of trans-platinum antitumor drugs Crit. Rev. Oncol. Hematol. 2000, 35, 109-120
9. Sheena, M. A.; Nicholas, P. F. Towards Antitumor Active trans -Platinum Compounds Eur. J. Inorg. Chem. 2009, 2009, 1293-1302
10. Coluccia, M.; Natile, G. trans -platinum complexes in cancer therapy Anticancer Agents Med. Chem. 2007, 7, 111-23
11. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumour metal compounds: More than theme and variations Dalton Trans. 2008, 183-194
12. Basolo, F.; Gray, H. B.; Pearson, R. G. Mechanism of Substitution Reactions of Complex Ions. Rates of Reaction of Some Platinum(II) and Palladium(II) Complexes with Pyridine J. Am. Chem. Soc. 1960, 82, 4200-4203
13. Berger, I.; Nazarov, A. A.; Hartinger, C. G.; Groessl, M.; Valiahdi, S. M.; Jakupec, M. A.; Keppler, B. K. A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? ChemMedChem 2007, 2, 505-514
14. Talman, E. G.; Bruning, W.; Reedijk, J.; Spek, A. L.; Veldman, N. Crystal and Molecular Structures of Asymmetric cis-and trans -Platinum(II/IV) Compounds and Their Reactions with DNA Fragments Inorg. Chem. 1997, 36, 854-861
15. Cleare, M. J.; Hoeschele, J. D. Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes Bioinorg. Chem. 1973, 2, 187-210
16. Timerbaev, A. R.; Hartinger, C. G.; Aleksenko, S. S.; Keppler, B. K. Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology Chem. Rev. 2006, 106, 2224-2248
17. Kratochwil, N. A.; Bednarski, P. J. Relationships between reduction properties and cancer cell growth inhibitory activities of cis-dichloro- and cis-diiodo-Pt(IV)-ethylenediamines Arch. Pharm. 1999, 332, 279-285
18. Kratochwil, N. A.; Ivanov, A. I.; Patriarca, M.; Parkinson, J. A.; Gouldsworthy, A. M.; Murdoch, P. D.; Sadler, P. J. Surprising reactions of iodo Pt(IV) and Pt(II) complexes with human albumin: Detection of Cys34 sulfenic acid J. Am. Chem. Soc. 1999, 121, 8193-8203
19. Miranda, P. O.; Padron, J. M.; Padron., J. I.; Vilar, J.; Martín, V. S. Prins-Type Synthesis and SAR Study of Cytotoxic Alkyl Chloro Dihydropyrans ChemMedChem 2006, 1, 323-329
20. Gallori, E.; Vettori, C.; Alessio, E.; Vilchez, F. G.; Vilaplana, R.; Orioli, P.; Casini, A.; Messori, L. DNA as a possible target for antitumor ruthenium(III) complexes-A spectroscopic and molecular biology study of the interactions of two representative antineoplastic ruthenium(III) complexes with DNA Arch. Biochem. Biophys. 2000, 376, 156-162
21. Hartinger, C. G.; Ang, W. H.; Casini, A.; Messori, L.; Keppler, B. K.; Dyson, P. J. Mass spectrometric analysis of ubiquitin-platinum interactions of leading anticancer drugs: MALDI versus ESI J. Anal. At. Spectrom. 2007, 22, 960-967
22. Peleg-Shulman, T.; Najajreh, Y.; Gibson, D. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles J. Inorg. Biochem. 2002, 91, 306-311
23. Casini, A.; Gabbiani, C.; Michelucci, E.; Pieraccini, G.; Moneti, G.; Dyson, P. J.; Messori, L. Exploring metallodrug-protein interactions by mass spectrometry: Comparisons between platinum coordination complexes and an organometallic ruthenium compound J. Biol. Inorg. Chem. 2009, 14, 761-770
24. Casini, A.; Guerri, A.; Gabbiani, C.; Messori, L. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies J. Inorg. Biochem. 2008, 102, 995-1006
25. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R. Z.; Intini, F. P.; Arnesano, F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L. Insights into the molecular mechanisms of protein platination from a case study: The reaction of anticancer Platinum(II) iminoethers with horse heart cytochrome c Biochemistry 2007, 46, 12220-12230
26. Cubo, L.; Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Jimenez-Barbero, J.; Navarro-Ranninger, C.; Quiroga, A. G. Solution Behaviour and Biomolecular Interactions of Two Cytotoxic trans -Platinum(II) Complexes Bearing Aliphatic Amine Ligands Chem. Eur. J. 2009, 15, 9139-9146
27. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Moneti, G.; Pieraccini, G. Exploring metallodrug-protein interactions by ESI mass spectrometry: The reaction of anticancer platinum drugs with horse heart cytochrome c ChemMedChem 2006, 1, 413-417
28. Gabbiani, C.; Casini, A.; Mastrobuoni, G.; Kirshenbaum, N.; Moshel, O.; Pieraccini, G.; Moneti, G.; Messori, L.; Gibson, D. Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis J. Biol. Inorg. Chem. 2008, 13, 755-764
29. Whittaker, J.; McFadyen, W. D.; Wickham, G.; Wakelin, L. P.; Murray, V. The interaction of DNA-targeted platinum phenanthridinium complexes with DNA Nucleic Acids Res. 1998, 26, 3933-3939
30. Quintal, S. M. O.; Qu, Y.; Quiroga, A. G.; Moniodis, J.; Nogueira, H. I. S.; Farrell, N. Pyridine-carboxylate complexes of platinum. Effect of N,O-chelate formation on model bifunctional DNA-DNA and DNA-protein interactions Inorg. Chem. 2005, 44, 5247-5253
31. Li, C.; Li, Z. Y.; Sletten, E.; Arnesano, F.; Losacco, M.; Natile, G.; Liu, Y. Z. Methionine Can Favor DNA Platination by trans-Coordinated Platinum Antitumor Drugs Angew. Chem., Int. Ed. 2009, 48, 8497-8500